Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg
Drug: Placebo identical to BI 1356 5mg
Drug: BI 1356
Drug: Glimepiride

Registration Number: NCT00622284

Lead Sponsor: Boehringer Ingelheim

Brief Summary: The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5.0 mg daily) compared to glimepiride given for 104 weeks as add-on therapy to preferably \> 1500 mg metformin in patients with type 2 diabetes mellitus with insufficient glycaemic control

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 1560

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
BI 1356 5mg, once daily	Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg	patient to receive a tablet containing 5mg BI 1356 plus one (two in US) inactive placebo capsule matching Glimepiride
BI 1356 5mg, once daily	BI 1356	patient to receive a tablet containing 5mg BI 1356 plus one (two in US) inactive placebo capsule matching Glimepiride
Glimepiride	Placebo identical to BI 1356 5mg	patient to receive 1mg or 2mg or 3mg (not in US) or 4mg Glimepiride capsule plus one inactive placebo tablet matching BI 1356 (plus one inactive placebo capsule in US)
Glimepiride	Glimepiride	patient to receive 1mg or 2mg or 3mg (not in US) or 4mg Glimepiride capsule plus one inactive placebo tablet matching BI 1356 (plus one inactive placebo capsule in US)

Primary Outcome Measures

Name	Time	Method
HbA1c Change From Baseline at Week 52	Baseline and week 52	This co-primary endpoint, change from baseline, reflects the Week 52 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and the number of previous anti-diabetic medications.
HbA1c Change From Baseline at Week 104	Baseline and week 104	This co-primary endpoint, change from baseline, reflects the Week 104 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and the number of previous anti-diabetic medications.

Secondary Outcome Measures

Name	Time	Method
HbA1c Change at Week 40	Baseline and week 40
HbA1c Change at Week 52	Baseline and week 52
HbA1c Change at Week 65	Baseline and week 65
HbA1c Change at Week 78	Baseline and week 78
HbA1c Change at Week 91	Baseline and week 91
Change in Baseline Lipid Parameter Low Density Lipoprotein (LDL) at Week 104	Baseline and week 104
Change in Baseline Lipid Parameter Triglyceride at Week 104	Baseline and week 104
Body Weight Change From Baseline at Week 52	Baseline and week 52	This key secondary endpoint, change from baseline, reflects the Week 52 body weight minus the baseline body weight. Means are treatment adjusted for baseline HbA1c, baseline weight and the number of previous antidiabetic-medications.
Body Weight Change From Baseline at Week 104	Baseline and week 104	This key secondary endpoint, change from baseline, reflects the Week 104 body weight minus the baseline body weight. Means are treatment adjusted for baseline HbA1c, baseline weight and the number of previous antidiabetic-medications.
Incidence of Hypoglycaemic Events up to 104 Weeks	Week 104	A hypoglycaemic event is defined as patient showing clinical signs suggestive of low blood glucose confirmed by a HBGM of below 55 mg/dl (3.1 mmol/L)
Incidence of Hypoglycaemic Events up to 52 Weeks	Week 52	A hypoglycaemic event is defined as patient showing clinical signs suggestive of low blood glucose confirmed by a home blood glucose monitoring (HBGM) of below 55 mg/dl (3.1 mmol/L)
Fasting Plasma Glucose (FPG) Change From Baseline at Week 52	Baseline and week 52	This change from baseline reflects the Week 52 FPG minus the Baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and the number of previous anti-diabetic medications.
Fasting Plasma Glucose (FPG) Change From Baseline at Week 104	Baseline and week 104	This change from baseline reflects the Week 104 FPG minus the Baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and number of previous anti-diabetic medications.
Percentage of Patients With HbA1c <7.0% at Week 52	Week 52	The percentage of patients with an HbA1c value below 7.0% at week 52, based upon patients with baseline HbA1c \>= 7%. If a patient did not have an HbA1c value at week 52 they were considered a failure, so HbA1c \>= 7.0%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications.
Percentage of Patients With HbA1c <7.0% at Week 104	Week 104	The percentage of patients with an HbA1c value below 7.0% at week 104, based upon patients with baseline HbA1c \>= 7%. If a patient did not have an HbA1c value at week 104 they were considered a failure, so HbA1c \>= 7.0%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications.
Percentage of Patients With HbA1c <6.5% at Week 52	Week 52	The percentage of patients with an HbA1c value below 6.5% at week 52, based upon patients with baseline HbA1c \>= 6.5%. If a patient did not have an HbA1c value at week 52 they were considered a failure, so HbA1c \>= 6.5%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications.
Percentage of Patients With HbA1c <6.5% at Week 104	Week 104	The percentage of patients with an HbA1c value below 6.5% at week 104, based upon patients with baseline HbA1c \>= 6.5%. If a patient did not have an HbA1c value at week 104 they were considered a failure, so HbA1c \>= 6.5%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications.
Percentage of Patients With HbA1c Lowering by 0.5% at Week 104	Week 104	Occurrence of relative efficacy response, defined as a lowering of 0.5% HbA1c at week 104
2 hr Postprandial Glucose (PPG) Change From Baseline at Week 104	Baseline and week 104	This change from baseline reflects the Week 104 2 hr PPG minus the Baseline 2hr PPG. Means are treatment adjusted for baseline HbA1c, baseline 2hr PPG and number of previous anti-diabetic medications.
HbA1c Change at Week 4	Baseline and week 4	Difference of base percent value \[Week x(%) - baseline (%)\]
HbA1c Change at Week 8	Baseline and week 8
HbA1c Change at Week 12	Baseline and week 12
HbA1c Change at Week 16	Baseline and week 16
HbA1c Change at Week 28	Baseline and week 28
HbA1c Change at Week 104	Baseline and week 104	The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement available during the first phase of the study. Last observation carried forward (LOCF) was used as imputation rule.
Change in Baseline Lipid Parameter Cholesterol at Week 104	Baseline and week 104
Change in Baseline Lipid Parameter HDL at Week 104	Baseline and week 104

Trial Locations

Locations (221): 1218.20.10030 Boehringer Ingelheim Investigational Site
🇺🇸
Topeka, Kansas, United States
1218.20.10035 Boehringer Ingelheim Investigational Site
🇺🇸
Los Angeles, California, United States
1218.20.10003 Boehringer Ingelheim Investigational Site
🇺🇸
Chula Vista, California, United States
1218.20.10009 Boehringer Ingelheim Investigational Site
🇺🇸
Federal Way, Washington, United States
1218.20.10026 Boehringer Ingelheim Investigational Site
🇺🇸
Renton, Washington, United States
1218.20.10045 Boehringer Ingelheim Investigational Site
🇺🇸
Perrysburg, Ohio, United States
1218.20.10036 Boehringer Ingelheim Investigational Site
🇺🇸
Murray, Utah, United States
1218.20.3307A Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours Cedex, France
1218.20.3307D Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours cedex, France
1218.20.10033 Boehringer Ingelheim Investigational Site
🇺🇸
Tempe, Arizona, United States
1218.20.10034 Boehringer Ingelheim Investigational Site
🇺🇸
West Palm Beach, Florida, United States
1218.20.3307B Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours cedex, France
1218.20.3312B Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours Cedex, France
1218.20.10028 Boehringer Ingelheim Investigational Site
🇺🇸
St. Louis, Missouri, United States
1218.20.35202 Boehringer Ingelheim Investigational Site
🇧🇬
Sofia, Bulgaria
1218.20.10020 Boehringer Ingelheim Investigational Site
🇺🇸
Los Angeles, California, United States
1218.20.35203 Boehringer Ingelheim Investigational Site
🇧🇬
Sofia, Bulgaria
1218.20.35204 Boehringer Ingelheim Investigational Site
🇧🇬
Stara Zagora, Bulgaria
1218.20.10024 Boehringer Ingelheim Investigational Site
🇺🇸
Philadelphia, Pennsylvania, United States
1218.20.3307C Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours cedex, France
1218.20.3307G Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours cedex, France
1218.20.10037 Boehringer Ingelheim Investigational Site
🇺🇸
Los Gatos, California, United States
1218.20.10031 Boehringer Ingelheim Investigational Site
🇺🇸
Columbus, Ohio, United States
1218.20.10013 Boehringer Ingelheim Investigational Site
🇺🇸
Mentor, Ohio, United States
1218.20.10006 Boehringer Ingelheim Investigational Site
🇺🇸
Omaha, Nebraska, United States
1218.20.10022 Boehringer Ingelheim Investigational Site
🇺🇸
Endwell, New York, United States
1218.20.3307E Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours cedex, France
1218.20.3311B Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours, France
1218.20.49024 Boehringer Ingelheim Investigational Site
🇩🇪
Bosenheim, Germany
1218.20.49004 Boehringer Ingelheim Investigational Site
🇩🇪
Aschaffenburg, Germany
1218.20.49015 Boehringer Ingelheim Investigational Site
🇩🇪
Frankfurt/Main, Germany
1218.20.3313B Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours, France
1218.20.3311D Boehringer Ingelheim Investigational Site
🇫🇷
Potigny, France
1218.20.49017 Boehringer Ingelheim Investigational Site
🇩🇪
Kelkheim, Germany
1218.20.49006 Boehringer Ingelheim Investigational Site
🇩🇪
Großheirath, Germany
1218.20.49005 Boehringer Ingelheim Investigational Site
🇩🇪
Künzing, Germany
1218.20.49007 Boehringer Ingelheim Investigational Site
🇩🇪
Nürnberg, Germany
1218.20.3311C Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours, France
1218.20.3313A Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours, France
1218.20.3314D Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours, France
1218.20.49010 Boehringer Ingelheim Investigational Site
🇩🇪
Leipzig, Germany
1218.20.49003 Boehringer Ingelheim Investigational Site
🇩🇪
Neuwied, Germany
1218.20.3309C Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours, France
1218.20.3314A Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours, France
1218.20.49016 Boehringer Ingelheim Investigational Site
🇩🇪
Hamburg, Germany
1218.20.49025 Boehringer Ingelheim Investigational Site
🇩🇪
Haag, Germany
1218.20.49021 Boehringer Ingelheim Investigational Site
🇩🇪
Hatten, Germany
1218.20.49028 Boehringer Ingelheim Investigational Site
🇩🇪
Bad Mergentheim, Germany
1218.20.49020 Boehringer Ingelheim Investigational Site
🇩🇪
Dresden, Germany
1218.20.49014 Boehringer Ingelheim Investigational Site
🇩🇪
Saarbrücken, Germany
1218.20.49022 Boehringer Ingelheim Investigational Site
🇩🇪
Berlin, Germany
1218.20.49019 Boehringer Ingelheim Investigational Site
🇩🇪
St. Ingbert/Oberwürzbach, Germany
1218.20.49029 Boehringer Ingelheim Investigational Site
🇩🇪
Hannover, Germany
1218.20.49018 Boehringer Ingelheim Investigational Site
🇩🇪
Flörsheim, Germany
1218.20.49012 Boehringer Ingelheim Investigational Site
🇩🇪
Köln, Germany
1218.20.85202 Boehringer Ingelheim Investigational Site
🇭🇰
Hong Kong, Hong Kong
1218.20.35304 Boehringer Ingelheim Investigational Site
🇮🇪
Co. Wexford, Ireland
1218.20.49030 Boehringer Ingelheim Investigational Site
🇩🇪
Speyer, Germany
1218.20.49026 Boehringer Ingelheim Investigational Site
🇩🇪
Wangen, Germany
1218.20.46003 Boehringer Ingelheim Investigational Site
🇸🇪
Göteborg, Sweden
1218.20.46002 Boehringer Ingelheim Investigational Site
🇸🇪
Malmö, Sweden
1218.20.10042 Boehringer Ingelheim Investigational Site
🇺🇸
Oklahoma City, Oklahoma, United States
1218.20.10023 Boehringer Ingelheim Investigational Site
🇺🇸
Indianapolis, Indiana, United States
1218.20.10032 Boehringer Ingelheim Investigational Site
🇺🇸
Cincinnati, Ohio, United States
1218.20.10007 Boehringer Ingelheim Investigational Site
🇺🇸
San Antonio, Texas, United States
1218.20.10029 Boehringer Ingelheim Investigational Site
🇺🇸
Salt Lake City, Utah, United States
1218.20.45006 Boehringer Ingelheim Investigational Site
🇩🇰
Aalborg, Denmark
1218.20.45001 Boehringer Ingelheim Investigational Site
🇩🇰
Aarhus C, Denmark
1218.20.45011 Boehringer Ingelheim Investigational Site
🇩🇰
Aarhus C, Denmark
1218.20.45013 Boehringer Ingelheim Investigational Site
🇩🇰
Aarhus C, Denmark
1218.20.45002 Boehringer Ingelheim Investigational Site
🇩🇰
Hvidovre, Denmark
1218.20.45003 Boehringer Ingelheim Investigational Site
🇩🇰
København NV, Denmark
1218.20.45007 Boehringer Ingelheim Investigational Site
🇩🇰
Odense, Denmark
1218.20.39034 Boehringer Ingelheim Investigational Site
🇮🇹
Catania, Italy
1218.20.39029 Boehringer Ingelheim Investigational Site
🇮🇹
Codogno (lo), Italy
1218.20.39021 Boehringer Ingelheim Investigational Site
🇮🇹
Genova, Italy
1218.20.39033 Boehringer Ingelheim Investigational Site
🇮🇹
Perugia, Italy
1218.20.39022 Boehringer Ingelheim Investigational Site
🇮🇹
Pordenone, Italy
1218.20.39032 Boehringer Ingelheim Investigational Site
🇮🇹
Roma, Italy
1218.20.44107 Boehringer Ingelheim Investigational Site
🇬🇧
Whitstable, United Kingdom
1218.20.3307F Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours cedex, France
1218.20.3307H Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours cedex, France
1218.20.3307I Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours cedex, France
1218.20.3310A Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours Cedex, France
1218.20.3310B Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours Cedex, France
1218.20.3310C Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours Cedex, France
1218.20.3310D Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours Cedex, France
1218.20.3310E Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours Cedex, France
1218.20.3312A Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours Cedex, France
1218.20.3312C Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours Cedex, France
1218.20.3312D Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours Cedex, France
1218.20.3308A Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours, France
1218.20.3308C Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours, France
1218.20.3308D Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours, France
1218.20.3308E Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours, France
1218.20.3308F Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours, France
1218.20.3309A Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours, France
1218.20.3309E Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours, France
1218.20.3309B Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours, France
1218.20.3309D Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours, France
1218.20.3311A Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours, France
1218.20.3313C Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours, France
1218.20.3313D Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours, France
1218.20.3314B Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours, France
1218.20.3314C Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours, France
1218.20.3314E Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours, France
1218.20.3314F Boehringer Ingelheim Investigational Site
🇫🇷
Joué les Tours, France
1218.20.3302A Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3301A Boehringer Ingelheim Investigational Site
🇫🇷
Nantes Cedex 1, France
1218.20.3302C Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3302D Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3302E Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3302G Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3302H Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3302I Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3303A Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3303B Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3303C Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3303D Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3303E Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3303G Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3303H Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3303I Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3304A Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3304B Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3304C Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3304D Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3304F Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3304H Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3305A Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3305B Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3305H Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3306A Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3306B Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3306D Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3306F Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3306G Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3306H Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.3306I Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1218.20.36204 Boehringer Ingelheim Investigational Site
🇭🇺
Békéscsaba, Hungary
1218.20.91022 Boehringer Ingelheim Investigational Site
🇮🇳
Chennai, India
1218.20.91025 Boehringer Ingelheim Investigational Site
🇮🇳
Gujarat, India
1218.20.36208 Boehringer Ingelheim Investigational Site
🇭🇺
Ajka, Hungary
1218.20.91027 Boehringer Ingelheim Investigational Site
🇮🇳
Patna, India
1218.20.35308 Boehringer Ingelheim Investigational Site
🇮🇪
Dublin, Ireland
1218.20.35306 Boehringer Ingelheim Investigational Site
🇮🇪
Co. Wexford, Ireland
1218.20.35310 Boehringer Ingelheim Investigational Site
🇮🇪
Co. Wexford, Ireland
1218.20.35303 Boehringer Ingelheim Investigational Site
🇮🇪
Waterford, Ireland
1218.20.31014 Boehringer Ingelheim Investigational Site
🇳🇱
Almere, Netherlands
1218.20.31016 Boehringer Ingelheim Investigational Site
🇳🇱
Beek en Donk, Netherlands
1218.20.31022 Boehringer Ingelheim Investigational Site
🇳🇱
Rilland, Netherlands
1218.20.48201 Boehringer Ingelheim Investigational Site
🇵🇱
Lodz, Poland
1218.20.49008 Boehringer Ingelheim Investigational Site
🇩🇪
Rednitzhembach, Germany
1218.20.49011 Boehringer Ingelheim Investigational Site
🇩🇪
Westerkappeln, Germany
1218.20.49002 Boehringer Ingelheim Investigational Site
🇩🇪
Sulzbach-Rosenberg, Germany
1218.20.49013 Boehringer Ingelheim Investigational Site
🇩🇪
Würzburg, Germany
1218.20.49027 Boehringer Ingelheim Investigational Site
🇩🇪
Saaldorf-Surheim, Germany
1218.20.49009 Boehringer Ingelheim Investigational Site
🇩🇪
Unterschneidheim, Germany
1218.20.36205 Boehringer Ingelheim Investigational Site
🇭🇺
Baja, Hungary
1218.20.36206 Boehringer Ingelheim Investigational Site
🇭🇺
Hódmezövásárhely, Hungary
1218.20.36207 Boehringer Ingelheim Investigational Site
🇭🇺
Mosonmagyarovar, Hungary
1218.20.35307 Boehringer Ingelheim Investigational Site
🇮🇪
Co. Cork, Ireland
1218.20.91026 Boehringer Ingelheim Investigational Site
🇮🇳
Tamilnadu, India
1218.20.39027 Boehringer Ingelheim Investigational Site
🇮🇹
Chieti, Italy
1218.20.39028 Boehringer Ingelheim Investigational Site
🇮🇹
Ravenna, Italy
1218.20.31023 Boehringer Ingelheim Investigational Site
🇳🇱
's Hertogenbosch, Netherlands
1218.20.39020 Boehringer Ingelheim Investigational Site
🇮🇹
Siena, Italy
1218.20.39030 Boehringer Ingelheim Investigational Site
🇮🇹
Roma, Italy
1218.20.31018 Boehringer Ingelheim Investigational Site
🇳🇱
Hoogwoud, Netherlands
1218.20.31011 Boehringer Ingelheim Investigational Site
🇳🇱
Ewijk, Netherlands
1218.20.31013 Boehringer Ingelheim Investigational Site
🇳🇱
Wildervank, Netherlands
1218.20.31019 Boehringer Ingelheim Investigational Site
🇳🇱
Roelofarendsveen, Netherlands
1218.20.47005 Boehringer Ingelheim Investigational Site
🇳🇴
Fevik, Norway
1218.20.47002 Boehringer Ingelheim Investigational Site
🇳🇴
Hamar, Norway
1218.20.47004 Boehringer Ingelheim Investigational Site
🇳🇴
Fornebu, Norway
1218.20.47001 Boehringer Ingelheim Investigational Site
🇳🇴
RUD, Norway
1218.20.48202 Boehringer Ingelheim Investigational Site
🇵🇱
Lodz, Poland
1218.20.47003 Boehringer Ingelheim Investigational Site
🇳🇴
Sandvika, Norway
1218.20.48207 Boehringer Ingelheim Investigational Site
🇵🇱
Krakow, Poland
1218.20.48210 Boehringer Ingelheim Investigational Site
🇵🇱
Bialystok, Poland
1218.20.48203 Boehringer Ingelheim Investigational Site
🇵🇱
Olsztyn, Poland
1218.20.48206 Boehringer Ingelheim Investigational Site
🇵🇱
Torun, Poland
1218.20.48205 Boehringer Ingelheim Investigational Site
🇵🇱
Warsaw, Poland
1218.20.27007 Boehringer Ingelheim Investigational Site
🇿🇦
Bellville, South Africa
1218.20.27002 Boehringer Ingelheim Investigational Site
🇿🇦
Cape Town, South Africa
1218.20.27004 Boehringer Ingelheim Investigational Site
🇿🇦
Lenasia, South Africa
1218.20.27005 Boehringer Ingelheim Investigational Site
🇿🇦
Lenasia, South Africa
1218.20.44108 Boehringer Ingelheim Investigational Site
🇬🇧
Baillieston, Glasgow, United Kingdom
1218.20.46004 Boehringer Ingelheim Investigational Site
🇸🇪
Uppsala, Sweden
1218.20.27003 Boehringer Ingelheim Investigational Site
🇿🇦
Pretoria, South Africa
1218.20.46001 Boehringer Ingelheim Investigational Site
🇸🇪
Malmö, Sweden
1218.20.44115 Boehringer Ingelheim Investigational Site
🇬🇧
Blackpool, United Kingdom
1218.20.44110 Boehringer Ingelheim Investigational Site
🇬🇧
Bradford on Avon, United Kingdom
1218.20.44114 Boehringer Ingelheim Investigational Site
🇬🇧
Cheadle, United Kingdom
1218.20.44109 Boehringer Ingelheim Investigational Site
🇬🇧
Chippenham, United Kingdom
1218.20.44102 Boehringer Ingelheim Investigational Site
🇬🇧
Buckshaw Village, Chorley, United Kingdom
1218.20.44116 Boehringer Ingelheim Investigational Site
🇬🇧
Chestfield, Whitstable, United Kingdom
1218.20.44111 Boehringer Ingelheim Investigational Site
🇬🇧
Westbury, United Kingdom
1218.20.44113 Boehringer Ingelheim Investigational Site
🇬🇧
Dundee, United Kingdom
1218.20.44105 Boehringer Ingelheim Investigational Site
🇬🇧
Edgbaston, Birmingham, United Kingdom
1218.20.44112 Boehringer Ingelheim Investigational Site
🇬🇧
Ely, United Kingdom
1218.20.44101 Boehringer Ingelheim Investigational Site
🇬🇧
Guildford, United Kingdom
1218.20.44106 Boehringer Ingelheim Investigational Site
🇬🇧
Trowbridge, United Kingdom
1218.20.44104 Boehringer Ingelheim Investigational Site
🇬🇧
Waterloo, Liverpool, United Kingdom
1218.20.44103 Boehringer Ingelheim Investigational Site
🇬🇧
Manchester, United Kingdom
1218.20.27006 Boehringer Ingelheim Investigational Site
🇿🇦
Durban, South Africa
1218.20.36202 Boehringer Ingelheim Investigational Site
🇭🇺
Makó, Hungary
1218.20.31012 Boehringer Ingelheim Investigational Site
🇳🇱
Oude Pekela, Netherlands
1218.20.35207 Boehringer Ingelheim Investigational Site
🇧🇬
Sofia, Bulgaria
1218.20.35201 Boehringer Ingelheim Investigational Site
🇧🇬
Sofia, Bulgaria
1218.20.91021 Boehringer Ingelheim Investigational Site
🇮🇳
Kochi, India
1218.20.91020 Boehringer Ingelheim Investigational Site
🇮🇳
Mumbai, India
1218.20.36201 Boehringer Ingelheim Investigational Site
🇭🇺
Miskolc, Hungary
1218.20.36203 Boehringer Ingelheim Investigational Site
🇭🇺
Szentes, Hungary
1218.20.91024 Boehringer Ingelheim Investigational Site
🇮🇳
Coimbatore, India
1218.20.91023 Boehringer Ingelheim Investigational Site
🇮🇳
Hyderabad, India
1218.20.48208 Boehringer Ingelheim Investigational Site
🇵🇱
Gdynia, Poland
1218.20.48209 Boehringer Ingelheim Investigational Site
🇵🇱
Warsaw, Poland
1218.20.10002 Boehringer Ingelheim Investigational Site
🇺🇸
Greer, South Carolina, United States
1218.20.85204 Boehringer Ingelheim Investigational Site
🇭🇰
Hong Kong, Hong Kong
1218.20.85201 Boehringer Ingelheim Investigational Site
🇭🇰
Hong Kong, Hong Kong